|
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2018 |
Jan 18 2018 |
53 |
Global |
$3,500.00 |
|
|
Cluster Headache Syndrome - Pipeline Review, H1 2018 |
Jan 18 2018 |
49 |
Global |
$2,000.00 |
|
|
Diarrhea - Pipeline Review, H1 2018 |
Jan 18 2018 |
154 |
Global |
$2,000.00 |
|
|
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H1 2018 |
Jan 18 2018 |
39 |
Global |
$3,500.00 |
|
|
Fatigue - Pipeline Review, H1 2018 |
Jan 18 2018 |
34 |
Global |
$2,000.00 |
|
|
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018 |
Jan 18 2018 |
106 |
Global |
$2,000.00 |
|
|
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H1 2018 |
Jan 18 2018 |
44 |
Global |
$3,500.00 |
|
|
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2018 |
Jan 18 2018 |
87 |
Global |
$2,000.00 |
|
|
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H1 2018 |
Jan 18 2018 |
35 |
Global |
$3,500.00 |
|
|
Post-Operative Pain - Pipeline Review, H1 2018 |
Jan 18 2018 |
218 |
Global |
$2,000.00 |
|
|
Tourette Syndrome - Pipeline Review, H1 2018 |
Jan 18 2018 |
82 |
Global |
$2,000.00 |
|
|
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2018 |
Jan 18 2018 |
34 |
Global |
$3,500.00 |
|
|
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2018 |
Jan 18 2018 |
80 |
Global |
$3,500.00 |
|
|
Hyperalgesia - Pipeline Review, H1 2018 |
Jan 18 2018 |
38 |
Global |
$2,000.00 |
|
|
Autism - Pipeline Review, H1 2018 |
Jan 18 2018 |
169 |
Global |
$2,000.00 |
|
|
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2018 |
Jan 18 2018 |
79 |
Global |
$2,000.00 |
|
|
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2018 |
Jan 18 2018 |
77 |
Global |
$3,500.00 |
|
|
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018 |
Jan 18 2018 |
68 |
Global |
$2,000.00 |
|
|
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2018 |
Jan 18 2018 |
34 |
Global |
$2,000.00 |
|
|
Restless Legs Syndrome - Pipeline Review, H1 2018 |
Jan 18 2018 |
47 |
Global |
$2,000.00 |
|
|
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2018 |
Jan 18 2018 |
83 |
Global |
$3,500.00 |
|
|
Typhoid Fever - Pipeline Review, H1 2018 |
Jan 18 2018 |
46 |
Global |
$2,000.00 |
|
|
Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation |
Dec 1 2017 |
72 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis |
Aug 1 2017 |
113 |
Global |
$6,995.00 |
|
|
Hepatitis Drug Development Pipeline Review, 2017 |
Aug 1 2017 |
209 |
Global |
$3,995.00 |
|
|
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 |
Aug 1 2017 |
254 |
Global |
$3,995.00 |
|
|
Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017 |
Aug 1 2017 |
138 |
Global |
$3,995.00 |
|
